S15 Ep36: Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Integrating recent clinical trial data into breast cancer treatment requires balancing efficacy with long-term safety, particularly regarding interstitial lung disease. Destiny Breast 11 demonstrates that TDXD followed by THP significantly improves pathologic complete response in high-risk HER2-positive early-stage breast cancer, while Destiny Breast 05 confirms TDXD’s superiority over TDM1 for invasive disease-free survival in patients with residual disease. In the first-line metastatic setting, TDXD combined with pertuzumab offers substantial progression-free survival benefits. Clinical management strategies for complex cases—such as triple-negative disease or ESR1-mutant hormone receptor-positive cancers—highlight the necessity of personalized approaches. Despite the efficacy of these targeted therapies, significant questions remain regarding the optimal sequencing of antibody-drug conjugates and the potential for synergistic effects when combining these agents with checkpoint inhibitors, necessitating further research to refine standard-of-care practices.